# A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors

> **NCT05171790** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 419 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** QL1706 injection

## Key facts

- **NCT ID:** NCT05171790
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-11
- **Primary completion:** 2021-12-31
- **Final completion:** 2023-12
- **Target enrollment:** 419 (ACTUAL)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05171790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05171790, "A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT05171790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*